Legis Daily

OTC Act of 2023

USA118th CongressHR-4626| House 
| Updated: 7/14/2023
Mariannette Miller-Meeks

Mariannette Miller-Meeks

Republican Representative

Iowa

Cosponsors (10)
Diana Harshbarger (Republican)Marjorie Taylor Greene (Republican)Ashley Hinson (Republican)Stephanie I. Bice (Republican)Young Kim (Republican)Maria Elvira Salazar (Republican)Nancy Mace (Republican)Jennifer A. Kiggans (Republican)Lori Chavez-DeRemer (Republican)Nicole Malliotakis (Republican)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Orally Taken Contraception Act of 2023 or the OTC Act of 2023 This bill requires the Food and Drug Administration (FDA) to issue guidance on the approval process for over-the-counter oral contraceptives so as to encourage drug manufacturers to submit applications for approval. The FDA must also evaluate (1) whether and to what extent consumers understand the labeling on oral contraceptives, and (2) whether the labeling could be improved.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 13, 2023
Introduced in House
Jul 13, 2023
Referred to the House Committee on Energy and Commerce.
Jul 14, 2023
Referred to the Subcommittee on Health.
  • July 13, 2023
    Introduced in House


  • July 13, 2023
    Referred to the House Committee on Energy and Commerce.


  • July 14, 2023
    Referred to the Subcommittee on Health.

Health

Drug safety, medical device, and laboratory regulationFamily planning and birth controlGovernment information and archivesGovernment studies and investigationsPrescription drugsWomen's health

OTC Act of 2023

USA118th CongressHR-4626| House 
| Updated: 7/14/2023
Orally Taken Contraception Act of 2023 or the OTC Act of 2023 This bill requires the Food and Drug Administration (FDA) to issue guidance on the approval process for over-the-counter oral contraceptives so as to encourage drug manufacturers to submit applications for approval. The FDA must also evaluate (1) whether and to what extent consumers understand the labeling on oral contraceptives, and (2) whether the labeling could be improved.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 13, 2023
Introduced in House
Jul 13, 2023
Referred to the House Committee on Energy and Commerce.
Jul 14, 2023
Referred to the Subcommittee on Health.
  • July 13, 2023
    Introduced in House


  • July 13, 2023
    Referred to the House Committee on Energy and Commerce.


  • July 14, 2023
    Referred to the Subcommittee on Health.
Mariannette Miller-Meeks

Mariannette Miller-Meeks

Republican Representative

Iowa

Cosponsors (10)
Diana Harshbarger (Republican)Marjorie Taylor Greene (Republican)Ashley Hinson (Republican)Stephanie I. Bice (Republican)Young Kim (Republican)Maria Elvira Salazar (Republican)Nancy Mace (Republican)Jennifer A. Kiggans (Republican)Lori Chavez-DeRemer (Republican)Nicole Malliotakis (Republican)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug safety, medical device, and laboratory regulationFamily planning and birth controlGovernment information and archivesGovernment studies and investigationsPrescription drugsWomen's health